NantKwest Gets A Shot In The Arm, CPRX Awaits FDA Word, FOMX Meets Phase 3 Goals

Today's Daily Dose brings you news about the near-term catalysts of Catalyst Pharma; progress in Entasis' gonorrhea study; positive results of Foamix Pharma's phase III papulopustular rosacea studies; Lannett's revised revenue outlook; NantKwest's cancer vaccine trial results; Nu Skin Enterprises' Q3 financial results and Rennova Health's reverse stock split.

from RTT - Biotech https://ift.tt/2QsexDA
via IFTTT